If accepted by the Food and Drug Administration, the first gene-altering treatment for leukemia will be the first gene therapy ever on the market. Quality control and consistency with this treatment are among the main concerns regarding its manufacturing process.
“The fact that it can be done means more people will go into the field and more companies will start developing these products,” said Pharmaceutical, Biotechnology and Medical Device Industries Partner Michael Werner. “I think we’re in for really exciting times."
Please note that email communications to the firm through this website do not create an attorney-client relationship between you and the firm. Do not send any privileged or confidential information to the firm through this website. Click "accept" below to confirm that you have read and understand this notice.